Extensive culturomics of 8 healthy samples enhances metagenomics efficiency.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 03 05 2019
accepted: 22 09 2019
entrez: 22 10 2019
pubmed: 22 10 2019
medline: 17 3 2020
Statut: epublish

Résumé

Molecular approaches have long led to the assumption that the human gut microbiota is dominated by uncultivable bacteria. The recent advent of large-scale culturing methods, and in particular that of culturomics have demonstrated that these prokaryotes can in fact be cultured. This is increasing in a dramatic manner the repertoire of commensal microbes inhabiting the human gut. Following eight years of culturomics approach applied on more than 900 samples, we propose herein a remake of the pioneering study applying a dual approach including culturomics and metagenomics on a cohort of 8 healthy specimen. Here we show that culturomics enable a 20% higher richness when compared to molecular approaches by culturing 1 archaeal species and 494 bacterial species of which 19 were new taxa. Species discovered as a part of previous culturomics studies represent 30% of the cultivated isolates, while sequences derived from these new taxa enabled to increase by 22% the bacterial richness retrieved by metagenomics. Overall, 67% of the total reads generated were covered by cultured isolates, significantly reducing the hidden content of sequencing methods compared to the pioneering study. By redefining culture conditions to recover microbes previously considered fastidious, there are greater opportunities than ever to eradicate metagenomics dark matter.

Identifiants

pubmed: 31634343
doi: 10.1371/journal.pone.0223543
pii: PONE-D-19-12468
pmc: PMC6802823
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0223543

Commentaires et corrections

Type : ExpressionOfConcernIn

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Microbiol. 2016 Nov 07;1:16203
pubmed: 27819657
BMC Microbiol. 2018 Oct 24;18(1):157
pubmed: 30355340
Anaerobe. 2015 Dec;36:73-8
pubmed: 26514403
BMC Biol. 2009 Nov 03;7:72
pubmed: 19886985
Clin Microbiol Infect. 2019 Apr 12;:null
pubmed: 30986553
Nature. 2016 May 04;533(7604):543-546
pubmed: 27144353
Clin Infect Dis. 2018 Feb 10;66(5):645-650
pubmed: 29020328
Int J Antimicrob Agents. 2019 Apr;53(4):355-361
pubmed: 30472293
Clin Microbiol Infect. 2012 Dec;18(12):1185-93
pubmed: 23033984
Eur J Clin Microbiol Infect Dis. 2013 Aug;32(8):1099
pubmed: 23430196
Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):561-70
pubmed: 25348607
Infect Dis Clin North Am. 2015 Mar;29(1):109-22
pubmed: 25677705
Int J Syst Evol Microbiol. 2013 Jul;63(Pt 7):2600-6
pubmed: 23264499
Microbiome. 2017 Aug 16;5(1):86
pubmed: 28810907
BMC Bioinformatics. 2012 Feb 14;13:31
pubmed: 22333067
PLoS One. 2019 Jan 10;14(1):e0210073
pubmed: 30629606
Int J Antimicrob Agents. 2014 Aug;44(2):117-24
pubmed: 25063078
Appl Environ Microbiol. 2014 Dec;80(24):7659-66
pubmed: 25281372
PLoS Pathog. 2012;8(5):e1002742
pubmed: 22693451
Clin Microbiol Rev. 2015 Jan;28(1):237-64
pubmed: 25567229
Gigascience. 2019 Mar 1;8(3):
pubmed: 30698687
Microbiome. 2018 May 24;6(1):94
pubmed: 29793532
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Physiol Rev. 2010 Jul;90(3):859-904
pubmed: 20664075
Int J Syst Evol Microbiol. 2014 Feb;64(Pt 2):346-51
pubmed: 24505072
Clin Infect Dis. 2009 Aug 15;49(4):543-51
pubmed: 19583519
Science. 2005 Jun 10;308(5728):1635-8
pubmed: 15831718
Appl Environ Microbiol. 2018 Sep 17;84(19):
pubmed: 30030229
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712

Auteurs

Ami Diakite (A)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Grégory Dubourg (G)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Niokhor Dione (N)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Pamela Afouda (P)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Sara Bellali (S)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Issa Isaac Ngom (II)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Camille Valles (C)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Matthieu Million (M)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Anthony Levasseur (A)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Frédéric Cadoret (F)

Assistance Publique-Hôpitaux de Marseille, Marseille, France.

Jean-Christophe Lagier (JC)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Didier Raoult (D)

Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH